News: ViroPharma Inc (VPHM.OQ)
32.00USD
1 Aug 2013
$-2.32 (-6.76%)
$34.32
$32.70
$33.16
$31.40
895,421
232,585
$35.18
$19.59
UPDATE 1-Halozyme drug delivery technology in doubt after trial halted
* Says partner ViroPharma halts trial after unexpected antibody production
Niche drugmaker ViroPharma attracts takeover interest: sources
NEW YORK - ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.
CORRECTED-UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest - sources
(In June 17 item, corrects in 3rd paragraph to show that ViroPharma is 19 years old)
Niche drugmaker ViroPharma attracts takeover interest: sources
NEW YORK - ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.
UPDATE 1-Niche drugmaker ViroPharma attracts takeover interest -sources
NEW YORK, June 17 - ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.
Orphan drugmaker ViroPharma attracts takeover interest -sources
NEW YORK, June 17 - ViroPharma Inc is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter.
- ViroPharma Management Discusses Q2 2013 Results - Earnings Call Transcript
- BioCryst's Lead Drug Candidate Will Face Challenges After FDA's Likely Peramivir Rejection
- Chimerix Goes Viral, Shares Could Double
- Halozyme: Drug Delivery Specialist With Multiple Catalysts
- This Metric Suggests You're Right to Own ViroPharma.
- This Week in Biotech
Press Releases
- ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
- ViroPharma To Participate In Two December Healthcare Investor Conferences
- ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) Prophylaxis Study Showed Safety Data of Escalating Doses in Patients With Hereditary Angioedema
- ViroPharma To Participate In Two November Healthcare Investor Conferences
- Health Canada Approves New Drug Submission for Cinryze™ (C1 inhibitor [human])
- ViroPharma To Release 2012 Third Quarter Financial Results On October 25, 2012
- ViroPharma Presents New Cinryze® (C1 Esterase Inhibitor [human]) Data On Site Of Care And Adherence At The 2012 Academy Of Managed Care Pharmacy Educational Conference
- ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
- ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
- ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference

